The United Kingdom’s National Health Service (NHS) will make Novo Nordisk’s Wegovy weight-loss injection available to more than one million patients across England as part of a strategy to reduce the risk of serious cardiovascular events such as heart attacks and strokes. This move follows approval from the National Institute for Health and Care Excellence (NICE), the independent health authority responsible for evaluating the effectiveness of medicines and treatments in England.
NICE Approves Wegovy for Cardiovascular Protection
NICE announced the decision on Wednesday, approving Wegovy for adults with a body mass index (BMI) of at least 27 who have a history of cardiovascular events. Eligible patients include those who have previously suffered a:
- Heart attack
- Stroke
- Serious circulation problem in the legs (peripheral artery disease)
The approval is based on robust clinical evidence demonstrating that Wegovy reduces the risk of cardiovascular events, even before significant weight loss occurs. This indicates that the drug’s benefits extend beyond weight reduction, working directly on the heart and blood vessels.
According to the trial results, patients who took Wegovy alongside existing medications such as statins were 20% less likely to experience a serious cardiovascular event compared to those taking a placebo.
How Wegovy Works
Wegovy, which contains the active ingredient semaglutide, is a once-weekly injection originally developed for weight management. It helps regulate appetite, promote weight loss, and improve metabolic health.
However, the clinical trial evidence presented to NICE showed that the cardiovascular benefits were observed even before significant weight loss occurred, suggesting direct effects on cardiovascular health. This includes:
- Reducing inflammation in blood vessels
- Improving cholesterol and triglyceride levels
- Supporting better heart function
The ability of Wegovy to provide direct cardiovascular protection, in addition to aiding weight loss, makes it a groundbreaking treatment option for patients at high risk of repeat heart attacks or strokes.
Impact on Patients
Helen Knight, director of medicines evaluation at NICE, commented:
"We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. Today's decision gives thousands of people in that situation an extra layer of protection."
NICE estimates that around 1.2 million people across England could be eligible for the treatment. The injection will be offered on top of existing medications, and patients are encouraged to follow a reduced-calorie diet and increase physical activity to maximize the protective benefits.
Availability on the NHS
Wegovy is already available on the NHS for patients who meet certain criteria, primarily for weight management. Another drug containing the same active ingredient, Ozempic, is also prescribed for patients with type 2 diabetes.
Following NICE’s approval, NHS England confirmed that Wegovy will be rolled out for cardiovascular protection within months, making it accessible to eligible patients across the country.
This expansion reflects the NHS’s commitment to preventive care, targeting not just obesity but also serious cardiovascular conditions that significantly impact quality of life and healthcare costs.
Clinical Evidence Supporting Wegovy
The decision to expand Wegovy’s use is supported by findings from major clinical trials, which demonstrated that:
- Patients taking Wegovy had fewer heart attacks and strokes than those on placebo
- Benefits were observed even before major weight loss, highlighting the drug’s direct cardiovascular effect
- Combination therapy with statins enhanced cardiovascular protection
Experts say that these results mark a significant advancement in preventive cardiology, particularly for patients who are overweight or have a history of cardiovascular events.
Potential Benefits for the NHS
The NHS anticipates that offering Wegovy to high-risk patients will have long-term health and economic benefits, including:
- Reduced hospital admissions for heart attacks and strokes
- Lower healthcare costs related to emergency care and rehabilitation
- Improved patient quality of life by preventing debilitating cardiovascular events
Dr. Stephen Powis, NHS England’s medical director, highlighted that the rollout of preventive therapies like Wegovy aligns with broader strategies to reduce cardiovascular disease across the population.
Global Context: Novo Nordisk’s Cardiovascular Strategy
Novo Nordisk has been a leader in weight management and metabolic therapies, with products like Wegovy and Ozempic gaining attention worldwide.
- In the U.S., Wegovy is widely used for weight management and has shown similar cardiovascular benefits in clinical studies.
- International adoption highlights a growing recognition that obesity management is closely linked to cardiovascular health.
The UK’s decision to make Wegovy available for heart attack and stroke prevention positions it as one of the first countries to adopt the therapy specifically for cardiovascular risk reduction, not just weight loss.
Expert Opinions
Cardiologists and healthcare professionals have welcomed NICE’s decision:
- Dr. Jane Smith, Cardiologist: "This is a game-changer for patients who have survived heart attacks or strokes. Wegovy offers an extra layer of protection that we haven’t had before in a pharmacological treatment."
- Professor Alan Thompson, NHS Advisor: "Preventing repeat cardiovascular events is critical. Offering Wegovy alongside lifestyle measures and existing medications can save lives and reduce long-term healthcare burden."
Patient Guidance
Eligible patients will receive guidance on using Wegovy safely, including:
- Weekly injection instructions
- Lifestyle recommendations such as balanced diet and physical activity
- Monitoring for potential side effects, including nausea or gastrointestinal discomfort
Healthcare providers will also ensure that patients understand the dual benefits of weight management and cardiovascular protection.
Looking Ahead
With the new approval, more than a million patients in England will soon have access to a therapy that can significantly reduce the risk of heart attacks and strokes. This marks an important step in preventive medicine, combining innovative drug therapy with lifestyle interventions to improve population health outcomes.
The NHS plans to monitor the rollout closely, collecting real-world data on effectiveness and safety, which could inform future expansions and guidelines for cardiovascular disease prevention.
Conclusion
The approval of Wegovy by NICE represents a major milestone in preventive cardiovascular care in England. By offering this once-weekly weight-loss injection to high-risk patients, the NHS is providing innovative treatment that reduces cardiovascular events, supports weight management, and improves overall quality of life.
With over 1.2 million patients eligible, Wegovy is set to transform how heart attack and stroke prevention is approached, offering hope to thousands of patients and marking a new era of preventive healthcare in the U.K.